Breaking News
Asia's oil shock nightmare has only just begun
This Claude-powered AI agent deleted a company's whole database -- and then gloated about it
Honestly guys, how can anyone watch this and justify it by blaming Hezbollah?
Weather Modification? Rainfall Returned to Iran After It Destroyed US Radar Installations
Top Tech News
Researcher wins 1 bitcoin bounty for 'largest quantum attack' on underlying tech
Interceptor-Drone Arms-Race Emerges
A startup called Inversion has introduced Arc, a space-based vehicle...
Mining companies are using cosmic rays to find critical minerals
They regrew a severed nerve - by shortening a bone.
New Robot Ants Work Like Real Insects To Build And Dismantle On Their Own
Russian scientists 'are developing the world's first drug to delay ageing' months after
Sam Altman's World ID Expands Biometric Identity Checks
China Tests Directed Energy Beam That Recharges Drones Mid-Flight
Jurassic Park might arrive sooner than expected, just with Dinobots.
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.